title: High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men--a nested case-control study.
abstract: Antibodies against phospholipid-binding plasma proteins, such as beta2-glycoprotein I (beta2-GPI) and prothrombin, are associated with thromboembolic events in patients with systemic lupus erythematosus and also in subjects with no evident underlying diseases. We wanted to examine whether increased levels of antibodies to negatively-charged phospholipids (cardiolipin), to phospholipid-binding plasma proteins beta2-GPI and prothrombin and to oxidised low-density lipoprotein (LDL) were associated with risk of deep venous thrombosis or pulmonary embolism in subjects with no previous thrombosis. The antibodies were measured in stored serum samples from 265 cases of deep venous thrombosis of the lower extremity or pulmonary embolism occurring during a median follow-up of about 7 years and from 265 individually matched controls. The study subjects were middle-aged men participating in a cancer prevention trial of alpha-tocopherol and beta-carotene and the cases of thromboembolic events were identified from nationwide Hospital Discharge Register. The risk for thrombotic events was significantly increased only in relation to antiprothrombin antibodies. As adjusted for body mass index, number of daily cigarettes and history of chronic bronchitis, myocardial infarction and heart failure at baseline, the odds ratio per one unit of antibody was 6.56 (95% confidence interval 1.73-25.0). The seven highest individual optical density-unit values of antiprothrombin antibodies were all confined to subjects with thromboembolic episodes. In conclusion, the present nested case-control study showed that high autoantibody levels against prothrombin implied a risk of deep venous thrombosis and pulmonary embolism and could be involved in the development of the thrombotic processes.
authors.affiliation: National Public Health Institute, Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Palosuo
authors.forename: J
authors.initials: J
authors.lastname: Virtamo
authors.forename: J
authors.initials: J
authors.lastname: Haukka
authors.forename: P R
authors.initials: PR
authors.lastname: Taylor
authors.forename: K
authors.initials: K
authors.lastname: Aho
authors.forename: M
authors.initials: M
authors.lastname: Puurunen
authors.forename: O
authors.initials: O
authors.lastname: Vaarala
mesh_terms: D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001991:Bronchitis / Q000453:epidemiology; D016022:Case-Control Studies; D015331:Cohort Studies; D015897:Comorbidity; D004311:Double-Blind Method; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology; D008175:Lung Neoplasms / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011516:Prothrombin / Q000276:immunology*; D011655:Pulmonary Embolism / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D012306:Risk; D012307:Risk Factors; D012907:Smoking / Q000097:blood / Q000276:immunology; D019851:Thrombophilia / Q000097:blood / Q000276:immunology*; D013924:Thrombophlebitis / Q000097:blood / Q000453:epidemiology / Q000276:immunology*; D014810:Vitamin E / Q000627:therapeutic use; D053482:beta 2-Glycoprotein I
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies; D006023:Glycoproteins; D008077:Lipoproteins, LDL; D053482:beta 2-Glycoprotein I; C099252:oxidized low density lipoprotein; D014810:Vitamin E; D011516:Prothrombin